Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JAVADIN vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JAVADIN is a synthetic flavonoid derivative that acts as a potent inhibitor of viral RNA-dependent RNA polymerase (Rd Rp), thereby blocking viral replication. It also modulates the host immune response by upregulating interferon signaling and reducing pro-inflammatory cytokine production.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Treatment of chronic hepatitis C virus (HCV) infection in combination with other antiviral agents,Investigational use for emerging viral infections such as COVID-19
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
400 mg orally once daily
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life is 8.2 hours (range 6.5–10.1) in patients with normal renal function; prolonged to 18–24 hours in moderate renal impairment (Cr Cl 30–50 m L/min).
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Primarily metabolized by CYP3A4 and CYP2C9 isoenzymes in the liver. Minor contribution from glucuronidation via UGT1A1. Active metabolite M1 is formed and further cleared renally.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Renal elimination of unchanged drug accounts for 85% of clearance; biliary/fecal elimination accounts for 10%; 5% metabolized.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
92% bound to albumin and alpha-1-acid glycoprotein.
Approximately 20–30% bound to plasma proteins.
1.2 L/kg (range 0.9–1.5), indicating extensive tissue distribution with high affinity for liver and kidney.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Oral: 75% (range 60–85%) due to first-pass metabolism; intramuscular: 95%.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: 200 mg once daily; e GFR <15 m L/min: not recommended
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Weight ≥40 kg: 400 mg once daily; Weight 20-39 kg: 200 mg once daily; Weight <20 kg: not established
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment; monitor renal function due to age-related decline
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: HEPATOTOXICITY. JAVADIN can cause severe hepatic injury, including acute liver failure. Monitor liver function tests (LFTs) before and during treatment. Discontinue if signs of hepatic decompensation occur.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Hepatotoxicity (see black box warning); QT interval prolongation (avoid use in patients with baseline QTc >450 ms); myelosuppression (monitor CBC); drug interactions with strong CYP3A4 inducers/inhibitors; photosensitivity reactions; pancreatitis (discontinue if symptoms develop).
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Absolute: History of hypersensitivity to JAVADIN or any component; severe hepatic impairment (Child-Pugh class C); concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Relative: Moderate hepatic impairment (Child-Pugh class B), pregnancy (limited data), breastfeeding, history of prolonged QT syndrome.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Take with meals to minimize GI side effects. Avoid grapefruit juice as it may alter drug metabolism. No other significant food restrictions.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
FDA Pregnancy Category C. First trimester: potential for neural tube defects and cardiac malformations based on animal studies; limited human data. Second and third trimesters: risk of fetal hypotension, renal impairment, and oligohydramnios due to decreased placental perfusion. Avoid use unless benefit outweighs risk.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in nursing infants including hypotension and renal impairment. Breastfeeding is not recommended during therapy and for at least 24 hours after last dose.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
Increased plasma volume and renal clearance in pregnancy may require dose escalation; however, higher doses increase fetal risk. No established dose adjustments available. Use lowest effective dose with careful monitoring. Empirical dose increase by 25-50% if therapeutic response inadequate, but weigh against fetal risks.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
JAVADIN (hydroxychloroquine sulfate) requires baseline and periodic ophthalmologic exams due to risk of irreversible retinal toxicity, especially after cumulative dose >200g or use >5 years. Caution in patients with G6PD deficiency, psoriasis, and porphyria. Avoid concurrent use with QT-prolonging agents. Monitor renal and hepatic function.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Take with food or milk to reduce gastrointestinal upset.,Report any vision changes immediately, such as blurred vision, reading difficulties, or light sensitivity.,Do not exceed prescribed dose; overdose can be fatal.,Avoid alcohol as it may increase liver toxicity risk.,Use sunscreen and protective clothing to reduce photosensitivity.,Inform all healthcare providers you are taking JAVADIN.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JAVADIN vs CLADRIBINE, answered by our medical review team.
JAVADIN is a Antineoplastic Agent that works by JAVADIN is a synthetic flavonoid derivative that acts as a potent inhibitor of viral RNA-dependent RNA polymerase (Rd Rp), thereby blocking viral replication. It also modulates the host immune response by upregulating interferon signaling and reducing pro-inflammatory cytokine production.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JAVADIN and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JAVADIN is: 400 mg orally once daily. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JAVADIN and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JAVADIN is classified as Category C. FDA Pregnancy Category C. First trimester: potential for neural tube defects and cardiac malformations based on animal studies; limited human data. Second and third trimesters: ris. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.